Pay in 4 interest-free payments of $7.26 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Pendulum will need to produce stronger clinical evidence to maintain relevance as orally available pharmaceutical alternatives emerge
It also helps to understand that the delivery method is part of the medicine
Patient advocacy organizations work to increase awareness of obesity as chronic disease requiring sustained medical management
The so-called GLP-1 patches available in the market containing herbal ingredients, may seem like a convenient option for weight management or diabetes control, but scientific evidence supporting their effectiveness is still limited
Survodutide (BI 456906) is a GLP-1/glucagon co-agonist which has progressed to phase 3 clinical trials as treatment for obesity (SYNCHRONIZE programme)
US$ 27.46
US$ 29.65
US$ 21.11
US$ 22.14
US$ 24.74
US$ 23.73
US$ 23.48
US$ 29.28
